Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Greenwich LifeSciences, Inc. - Common stock (NQ:GLSI)

28.80 -0.93 (-3.13%)
Streaming Delayed Price Updated: 10:06 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Greenwich LifeSciences, Inc. - Common stock

< Previous 1 2 Next >
News headline image
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Set to Join Russell 2000® Index
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
From Greenwich LifeSciences, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.